Key Points
-
Tilray’s revenue grew at a good clip in its last quarter, but that was due to an acquisition.
-
The company’s cannabis sales fell 13%, and it swung back to an operating loss.
-
With U.S. legalization still hard to predict, and regulatory challenges in other countries, a record low alone is no reason to buy.
-
The cannabis industry has been a massive disappointment in recent years, and even most industry leaders haven’t escaped the bloodbath. Take, for instance, Tilray Brands (NASDAQ:TLRY), one of the largest players in the Canadian cannabis market. Tilray has significantly underperformed the broader market over the past half-decade, losing more than 90% of its value. The company is now near record lows. Is Tilray stock a buy at current levels, or would investors be catching a falling knife?
Image source: Getty Images.
Missed AI’s “Act 1”? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But according to our analysts, we’re only at the end of “Act 1″—the R&D phase. “Act 2” is the global rollout. Continue »
What happened to Tilray Brands?
Tilray Brands faces a difficult regulatory landscape in the cannabis market. Recreational use of the substance remains illegal at the federal level in the U.S. It is legal in Canada, where the company is headquartered, but that market has its own challenges.
Obtaining the proper licenses in Canada is a complex and time-consuming process. The market north of the border is also characterized by stiff competition and persistent supply gluts. Although Tilray is an industry leader, these problems have harmed its financial results. The company has diversified its business in response.
It now operates four segments: cannabis, beverage, wellness (which offers a variety of products, including hemp-based foods), and distribution (which focuses on selling pharmaceutical products in certain international markets). But even a more diversified pool of operations has done little to improve Tilray’s financial results.
In the first quarter of its fiscal year 2027, which ended on Aug. 31, Tilray’s revenue increased by 23% year over year to a record $257 million. That looks impressive at first glance, but Tilray’s top line did not grow that much organically. Earlier this year, it acquired certain assets associated with BrewDog, a craft brewery based in the United Kingdom.
This acquisition added $55.9 million in revenue to the company’s total for the period. If we subtract that from Tilray’s total revenue, its top line comes in at $201.2 million for the period, down about 4% year over year.
This includes cannabis revenue of $56.1 million, which dropped 13% year over year. Wellness revenue stayed roughly flat at $15.3 million, while distribution revenue was $84.3 million, 14% higher than the year-ago period. Beverage revenue minus the BrewDog acquisition declined 18% year over year to $45.6 million.
So of Tilray’s four business segments, only one posted strong year-over-year organic sales growth. Meanwhile, the company’s operating loss was $24.1 million, compared with $2.1 million in operating income in the year-ago period. It also turned in a net loss per share of $0.32, after breaking even in the comparable period of the previous fiscal year.
What does the future hold?
Tilray’s poor financial results aren’t the only problem. The company also faces a highly uncertain future, even given recent regulatory progress in the U.S. The federal government reclassified certain medical cannabis products and has discussed broader reclassification, which could encompass recreational cannabis.
But the substance remains illegal at the federal level. That means it still cannot be transported across state lines, among other restrictions. So, Tilray’s opportunities in the U.S. remain severely limited. Will that change anytime soon? It’s hard to say. Nobody knows if or when the U.S. will legalize recreational use of cannabis at the federal level.
Even if it does, Tilray might face problems similar to those it faced in Canada. What about other countries? Could Tilray bounce back by tapping into international markets? Unfortunately, that also seems unlikely. For instance, Germany legalized recreational cannabis in 2024, but this did very little to boost Tilray’s results, despite the company’s presence in the country.
Germany allowed people to grow cannabis at home (within certain limits) or join non-commercial cannabis clubs. The law left little room for commercial companies like Tilray. So, the pot grower faces a stringent regulatory environment practically wherever it goes, and that might not change anytime soon. Tilray is unlikely to bounce back.
Investing in the stock, even at its record low, isn’t worth the trouble.
Should you buy stock in Tilray Brands right now?
Before you buy stock in Tilray Brands, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tilray Brands wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 21, 2026.
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.